product summary
Loading...
company name :
Novus Biologicals
other brands :
IMGENEX
product type :
antibody
product name :
p19ARF/CDKN2A Antibody (12-A1-1)
catalog :
NB200-169
quantity :
0.1 ml (also 0.025 ml)
price :
409 USD
clonality :
monoclonal
host :
rat
conjugate :
nonconjugated
clone name :
12-A1-1
reactivity :
human, mouse
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section, immunohistochemistry - frozen section
more info or order :
citations: 6
Reference |
---|
Apicelli A, Maggi L, Hirbe A, Miceli A, Olanich M, Schulte Winkeler C, et al. A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Mol Cell Biol. 2008;28:1068-80 pubmed
|
Hernando E, Charytonowicz E, Dudas M, Menendez S, Matushansky I, Mills J, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13:748-53 pubmed
|
Klochendler Yeivin A, Picarsky E, Yaniv M. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex. Mol Cell Biol. 2006;26:2661-74 pubmed
|
image
image 1 :

Western Blot: p19ARF/CDKN2A Antibody (12-A1-1) [NB200-169] - Analysis of endogenous p19Arf using NB200-169. Total cell lysates (25 ug) from NIH3T3 cells, which have deleted the Arf gene (Lanes 1) and from wild type mouse embryo fibroblasts (MEFs) at passage 6, which express p19Arf (Lanes 2), were resolved by SDS-PAGE. The membrane was probed with 1ug/ml purified p19Arf (NB200-169).
product information
brand :
Novus Biologicals, a Bio-Techne brand
catalog number base :
NB200-169
SKU :
NB200-169
product name :
p19ARF/CDKN2A Antibody (12-A1-1)
description :
The p19ARF/CDKN2A Antibody (12-A1-1) from Novus Biologicals is a rat monoclonal antibody to p19ARF/CDKN2A. This antibody reacts with hamster (negative),human (negative),mouse. The p19ARF/CDKN2A Antibody (12-A1-1) has been validated for the following applications: ELISA,Immunohistochemistry,Immunoprecipitation,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Immunocytochemistry/ Immunofluorescence,IF/IHC,Western Blot.
target :
p19ARF/CDKN2A
unit size :
0.1 ml (also 0.025 ml)
category :
Primary Antibodies
buffer :
Ascites
clonality :
Monoclonal
clone :
12-A1-1
conjugate :
Unconjugated
host :
Rat
immunogen :
A synthetic peptide made to a sequence (within residues 1-100) of mouse p19ARF/CDKN2A. [UniProt# Q64364]
isotype :
IgG2b
purity :
Unpurified
species :
Hamster (Negative),Human (Negative),Mouse
specificity :
This antibody is specific for murine p19ARF/CDKN2A
storage :
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
theoretical molecular weight :
19 kDa
gene symbol :
Cdkn2a
accessionNumbers :
Q64364
applications :
ELISA,Immunohistochemistry,Immunoprecipitation,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Immunocytochemistry/ Immunofluorescence,IF/IHC,Western Blot
USD :
399
USD 2025 :
409 USD
alt names :
alternative reading frame, ARF, ARF-INK4a, CDK4I, CDKN2A, Cyclin-dependent kinase 4 inhibitor A, cyclin-dependent kinase inhibitor 2A, cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4), cyclin-dependent kinase inhibitor 2A, isoform 3, cyclin-dependent kinase inhibitor 2A, isoforms 1/2, cyclin-dependent kinase inhibitor protein, INK4, INK4a, Ink4a/Arf, INK4a-ARF, mitochondrial smARF', MTS1, p14, p14ARF, P16, p16(INK4a), p16-INK4, p16INK4a, p16-INK4a, P19, p19 ARF , p19ARF, Pctr1
more info or order :
company information

Novus Biologicals
10771 E Easter Ave
Centennial, CO 80112
Centennial, CO 80112
novus@novusbio.com
https://www.novusbio.com3037301950
headquarters: USA
Novus Biologicals licenses, manufactures, and markets antibodies to over 20,000 unique targets to support a wide array of research areas. Novus is built on honesty, collaboration and strong relationships and continues to provide quality tools that accelerate research. Every product is backed by our 100% guarantee.
related products
browse more products
questions and comments